Oak Ridge, TN – September 12, 2024 — Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces a review published in the journal Cardiorenal Medicine that delves into the intricate landscape of cardiorenal syndrome (CRS) and highlights the pivotal role of Blood Volume Analysis (BVA) in improving patient care and outcomes. 

Key findings:

• BVA as a diagnostic tool enhances the precision of diuretic and red cell therapies, significantly elevating the effectiveness of conventional care.
• Integrating BVA in CRS care has clinical implications, including personalized treatment and improved outcomes.
• The heart-kidney relationship in CRS underscores the need for precise, personalized care, where BVA plays a crucial role.

The review titled, “Blood Volume Analysis and Cardio-renal syndrome: from bench to bedside,” explored the relationship between the heart and kidneys in CRS and discussed the usage of BVA in assessing and managing this challenging syndrome. Expert contributors included John Lynn Jefferies, MD, MBA, MPH, FACC, FAHA, FAAP, FHFSA, FRCPE, FESC, Cynthia Ann Stavish, MSN, APRN, ACNS-BC, PHN, Marc A. Silver, MD, FACC, FAHA, FHFSA, Javed Butler, MD, MPH, MBA, Harvey David Humes, MD, and John Strobeck, MD, PhD, FACC.

“CRS involves the complex interplay of cardiac and renal dysfunction” said John L. Jefferies, MD, Daxor’s Chief Medical Officer. “BVA is a highly accurate (98%) technique for measuring total blood and red blood cell volumes, informing the evaluation and treatment of CRS, including its subtypes, pathophysiology, and clinical significance. Integrating BVA into CRS management optimizes personalized therapy and enhances patient outcomes.”